Strategic Alliances

Celldex is interested in exploring collaborative discussions to leverage our antibody-based APC Targeting Technology and our Notch technology platform, as well as development and commercialization partnerships around our on-going clinical programs. Our objective is to enter into partnerships that will enhance our mutual ability to advance novel science and improve our ability to develop truly life-changing therapies for our patients.

Our current portfolio of clinical development candidates will also form the basis for co-development and commercialization partnerships, as Celldex wishes to leverage the marketing and distribution capabilities of major pharmaceutical partners for our immunotherapies. Our broad intellectual property portfolio and scientific expertise will enable us to establish meaningful commercial relationships in our core areas of disease management – oncology, infectious disease and auto-immune disorders.

Clinical Development Programs

NAME	INDICATION	DESCRIPTION	STATUS
CDX-110	Glioblastoma	EGFRvIII anti-tumor therapy	Phase II
CDX-110	Ovarian/Prostate Cancer	EGFRvIII anti-tumor therapy	Phase I
CDX-1307	Colon / Bladder / Pancreatic	Antibody-targeted anti-tumor therapy	Phase I
CDX-1307	Breast Cancer	Antibody-targeted anti-tumor therapy	Phase I
CDX-1401	Multiple tumor types	Antibody-targeted anti-tumor therapy	Preclinical
CDX-2101	Hepatitis B	Targeted therapeutic HBV vaccine	IND-ready
CDX-2401	HIV antiviral	Antibody-targeted anti-infective	Preclinical

Celldex is currently seeking the following types of business partnerships:

• Clinical Development and Commercialization Partnership for our therapeutic vaccine for hepatitis B – initially targeting China as the most urgent clinical need.
• Pre-clinical R&D relationships using proprietary antigens and/or targets that could form the basis for an APC antibody-antigen targeted therapy.
• Pre-clinical R&D relationships to further advance our auto-immune programs that leverage our IP and experience within the Notch signaling pathway.

We are confident that we offer a range of highly-innovative approaches to manipulating the human immune system to improve disease management and clinical outcomes, and see exciting partnering opportunities for companies with strong immunotherapy franchises.

The following partnerships have already been established:

The Ludwig Institute for Cancer Research – In October 2006, Celldex entered a multi-year clinical research collaboration focusing on a series of tumor-associated antigens (TAAs) for use in Celldex’s Antigen Presenting Cell (APC) Targeting Technology™. These antigens, previously identified and characterized immunologically by LICR, will add substantially to new Celldex development programs for a range of cancer types. Three of these antigens (NY-ESO-1, MAGE3, and MelanA) are being studied in non-small cell lung, ovarian, and bladder cancers, as well as melanoma, in an extended series of Phase I/II programs conducted by the LICR and its collaborators.

Medarex – Through our formation from within Medarex in October 2005, Celldex retains the exclusive right to use the Medarex ‘huMAb’ mice for the development of antibody-based immunotherapies (our core APC Targeting Technology), as well as the right to enter into five (5) therapeutic antibody collaborations around novel targets.

Rockefeller University – Celldex has licensed intellectual property from Rockefeller to target the DEC-205 family of mannose receptors in human dendritic cells, leveraging discoveries from the laboratories of Professor Ralph Steinman and Michel Nussenzweig. Professors Steinman and Nussenzweig also sit on our Scientific Advisory Board. DEC-205 is a key receptor for certain antigen processing pathways, and having access to this IP greatly enhances our ability to develop highly-targeted immunotherapies.

Celldex is also collaborating with Rockefeller to develop a novel vaccine against HIV, the virus known to cause AIDS. This project is supported through a $14 million grant from the Grand Challenges for Global Health program within the Bill & Melinda Gates Foundation. The project is using these same human antibodies to DEC-205 receptors to selectively initiate robust immune responses against specifically selected HIV antigens.